Search our Database of Scientific Publications and Authors

I’m looking for a

    820 results match your criteria Asia-Pacific Journal of Clinical Oncology [Journal]

    1 OF 17

    End-of-life care of oncology inpatients: Are we getting it right?
    Asia Pac J Clin Oncol 2018 Jun 13. Epub 2018 Jun 13.
    Australian National University Medical School, The Canberra Hospital, Canberra, Australian Capital Territory, Australia.
    Aim: To examine the current patterns of end-of-life care of medical oncology patients dying in an Australian tertiary acute hospital setting in order to determine potential areas for improvement.

    Methods: A retrospective observational study was undertaken of 295 consecutive adult medical oncology inpatients dying between 2010 and 2015. Charts were reviewed for evidence of (1) resuscitation plans, (2) acute interventions in the 48-h period prior to death, (3) palliative care involvement and (4) recognition of the dying patient and comfort care plans. Read More

    Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
    Asia Pac J Clin Oncol 2018 Jun 13. Epub 2018 Jun 13.
    Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Tao-Yuan, Taiwan.
    Aim: Pazopanib is a multitargeted tyrosine kinase inhibitor used as a standard treatment for chemotherapy-refractory recurrent or metastatic soft tissue sarcoma. This study aimed to evaluate the efficacy and safety of pazopanib for treatment of metastatic soft tissue sarcoma in the Asian population.

    Methods: Fifty patients with chemotherapy-refractory recurrent or metastatic soft tissue sarcoma, who had received pazopanib treatment between 2015 and 2016 were enrolled. Read More

    The current status of multimodality treatment for unresectable locally advanced esophageal squamous cell carcinoma.
    Asia Pac J Clin Oncol 2018 Jun 5. Epub 2018 Jun 5.
    Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
    A multimodality approach plays a key role in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Currently, definitive chemoradiotherapy (dCRT) using 5-fluorouracil (5-FU) plus cisplatin with radiotherapy is the standard treatment in this population. dCRT regimens using 5-FU plus leucovorin plus oxaliplatin (FOLFOX), and carboplatin plus paclitaxel have been investigated in prospective clinical trials. Read More

    Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Asia Pac J Clin Oncol 2018 Jun 5. Epub 2018 Jun 5.
    School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.
    Aim: To validate and compare the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx) for measuring chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.

    Methods: Patients were assessed with the EORTC QLQ-CIPN20, FACT/GOG-Ntx, National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) and World Health Organization criterion of CIPN (WHO-CIPN) from baseline up to 10 assessment points. Internal consistency reliability, convergent validity, discriminant validity and responsiveness of the EORTC QLQ-CIPN20 and FACT/GOG-Ntx were evaluated, respectively. Read More

    Lymph nodes metastasis in cervical cancer: Incidences, risk factors, consequences and imaging evaluations.
    Asia Pac J Clin Oncol 2018 May 31. Epub 2018 May 31.
    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
    Aim: The aim of this study was to determine the incidence, risk factors, consequences and accuracy of imaging evaluation of lymph node (LN) metastasis in a cohort of 406 patients treated with radical hysterectomy (RH), lymphadenectomy of pelvic LN (PLN) and para-aortic LN (PALN), which was performed primarily by one physician.

    Methods: From February 2001 to November 2015, patients with cervical cancer of FIGO stage IB were included, if they received RH of class III or type C performed by Dr. M. Read More

    FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center.
    Asia Pac J Clin Oncol 2018 May 28. Epub 2018 May 28.
    Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
    Aim: Fluorescence in situ hybridization (FISH) is an important ancillary tool for the classification of bone/soft tissue (BST) tumors. The aim of this study was to evaluate the contribution of FISH to the final classification of common BST entities in the molecular pathology department of the Royal Prince Alfred Hospital (RPAH), which is one of the most important referral centers for the management of sarcomas in Australia.

    Methods: All routine diagnostic FISH tests performed on BST formalin-fixed paraffin embedded (FFPE) tissue specimens at the RPAH in a 5-year period (February, 2010-November, 2015) were reviewed. Read More

    A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib.
    Asia Pac J Clin Oncol 2018 May 21. Epub 2018 May 21.
    Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
    Aim: A sustained proportion of advanced hepatocellular carcinoma (HCC) patients worldwide received either chemotherapy or sorafenib. However, to date, effective and convenient biomarkers to predict their therapeutic outcomes remained elusive. Hypothyroidism was associated with favorable anticancer treatment outcomes in several advanced cancers. Read More

    Effect of neurological monitoring in postoperative 5-15 days residual thyroidectomy after primary thyroid cancer surgery.
    Asia Pac J Clin Oncol 2018 May 16. Epub 2018 May 16.
    Department of Thyroid Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
    Aim: To explore the application of intraoperative neurological monitoring in residual thyroidectomy 5-15 days after thyroid cancer operation and the influence on postoperative serum thyroglobulin (Tg), recurrent laryngeal nerve and function of parathyroid glands.

    Methods: Material of patients receiving thyroid surgery from January 2010 to December 2016 was retrospectively analyzed. Cases meeting with standards were enrolled for analysis and the patients were divided into neurological monitoring group and non-neurological monitoring group in line with the use of neurological monitoring during the operation. Read More

    Downregulated miR-17, miR-29c, miR-92a and miR-214 may be related to BCL11B overexpression in T cell acute lymphoblastic leukemia.
    Asia Pac J Clin Oncol 2018 May 11. Epub 2018 May 11.
    Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
    Aim: BCL11B overexpression is a characteristic of most T cell acute lymphoblastic leukemia (T-ALL) cases, and downregulated BCL11B in leukemic T cells inhibits cell proliferation and induces apoptosis. The purpose of this study was to analyze the miRNA expression pattern that may be related to BCL11B regulation in T-ALL.

    Methods: Quantitative real-time PCR was used to detect the miRNAs miR-17-3p, miR-17-5p, miR-29c-3p, miR-92a-3p, miR-214-3p and miR-214-5p, the BCL11B expression level in peripheral blood mononuclear cells which was obtained from 17 de novo and untreated T-ALL patients, and 15 healthy individuals (HIs) served as control. Read More

    Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma.
    Asia Pac J Clin Oncol 2018 May 11. Epub 2018 May 11.
    Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
    Objective: Several members of protocadherins (PCDHs) have been identified as tumor suppressor genes in human carcinogenesis, but little is known about PCDH19. The aim of the present study was to assess the expression and methylation of PCDH19 in hepatocellular carcinoma (HCC).

    Methods: The RNA-seq data from The Cancer Genome Atlas Database were downloaded and used for analyzing PCDH19 expression in HCC patients and normal liver tissues. Read More

    Oncologist provision of smoking cessation support: A national survey of Australian medical and radiation oncologists.
    Asia Pac J Clin Oncol 2018 Apr 29. Epub 2018 Apr 29.
    Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
    Aim: Continued smoking in patients diagnosed with cancer affects treatment outcomes and overall survival. With national surveys of Australian medical oncologists (MO) and radiation oncologists (RO) we sought to determine current clinical practices, preferences and barriers in providing patient smoking cessation support.

    Methods: Oncologist members of the Medical Oncology Group of Australia (n = 452) and Trans-Tasman Radiation Oncology Group (n = 230) were invited to participate in a multiple choice survey exploring smoking cessation practices and beliefs. Read More

    Interpolation to define clinical tumor stage in prostate cancer using clinical description of digital rectal examination.
    Asia Pac J Clin Oncol 2018 Apr 27. Epub 2018 Apr 27.
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
    Aim: This study aims to assess characteristics of patients with prostate cancer for whom clinical T stage category (cT) was not documented in the medical record and assess whether specialists had concordant conclusions regarding cT based on digital rectal examination (DRE) notes.

    Methods: Data from the Prostate Cancer Outcome Registry - Victoria (PCOR-Vic) were interrogated. Four specialists independently assigned cT to DRE notes. Read More

    Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis.
    Asia Pac J Clin Oncol 2018 Apr 19. Epub 2018 Apr 19.
    Sydney Medical School, Northern Clinical School, University of Sydney, Sydney, NSW, Australia.
    Aim: To report on the pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+NSCLC) in a real-world retrospective cohort from an Australian tertiary referral center.

    Methods: Individuals with a pathological diagnosis of ALK+NSCLC via immunohistochemistry and fluorescence in situ hybridization and a radiological diagnosis of stage IV disease were eligible. Patients were identified via the Pathology Department specimen database and electronic patient chart review. Read More

    Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.
    Asia Pac J Clin Oncol 2018 Apr 16. Epub 2018 Apr 16.
    Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.
    Aim: To explore the utility of prostate specific membrane antigen (PSMA)-positron emission tomography (PET)/computed tomography (CT) in addition to conventional imaging prior to definitive external beam radiation treatment (EBRT) for prostate cancer.

    Methods: All men undergoing PSMA-PET/CT prior to definitive EBRT for intermediate and high-risk prostate cancer were included in our ethics approved prospective database. For each patient, clinical and pathological results, in addition to scan results including site of PSMA positive disease and number of lesions, were recorded. Read More

    Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: The first real-life experience in Asia.
    Asia Pac J Clin Oncol 2018 Apr 16. Epub 2018 Apr 16.
    Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
    Introduction: A substantial survival benefit with chemohormonal therapy has been proven by the CHAARTED and STAMPEDE studies, and this clinical approach has emerged as the standard of care for patients with metastatic hormone-naïve prostate cancer (mHSPC). However, because its clinical efficacy and tolerability in Asian patients remains uncertain, this study aims to evaluate preliminary results of its use in Hong Kong.

    Methods: The clinical records of mHSPC patients treated with chemohormonal therapy from all six public oncology centers in Hong Kong between January 2015 and July 2016 were reviewed. Read More

    Exploring treatment decision-making in cancer management for rural residents: Patient and provider perspectives on a recently established regional radiotherapy service.
    Asia Pac J Clin Oncol 2018 Mar 26. Epub 2018 Mar 26.
    Western Australian Centre for Rural Health, The University of Western Australia, Crawley, Australia.
    Aim: The aim of this study was to examine stakeholders' views of how the establishment of the South West Radiation Oncology Service in Bunbury, Western Australia, has affected treatment decision-making, and the extent to which patients are involved in the decision-making process.

    Methods: Semi-structured in-depth interviews were undertaken with 21 service providers involved in the treatment and care of people with cancer, and 17 adults diagnosed with cancer who opted to undergo radiotherapy (RT) treatment at the Service. Data were subject to thematic analysis using the qualitative data analysis software NVivo 10. Read More

    Exosomal tetraspanins as regulators of cancer progression and metastasis and novel diagnostic markers.
    Asia Pac J Clin Oncol 2018 Mar 25. Epub 2018 Mar 25.
    Department of Biochemistry, Cancer Biology Lab, Institute of Science, Gandhi Institute of Technology and Management (GITAM) (Deemed to be university), Visakhapatnam, India.
    Exosomes are cell-cell communicators emerging as a new paradigm for noninvasive diagnosis and prognosis of treatment response. Exosomal tetraspanin proteins like CD63, CD9 and CD81 play a critical role in sorting, selective recruitment of biomolecules, target selection, cell-specific entry, capturing, angiogenesis and vasculogenesis. These tetraspanins are being used as markers for oral, colorectal and colon cancers and glioblastoma. Read More

    Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
    Asia Pac J Clin Oncol 2018 Mar 24. Epub 2018 Mar 24.
    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China.
    Aim: Patients with advanced nonsquamous nonsmall cell lung cancer (NSCLC) who experienced progression with two or more lines chemotherapy have no treatment options that clearly confer a survival benefit. As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, apatinib has a certain antitumor effect for various solid tumors. The present study evaluated the efficacy and safety of apatinib in advanced nonsquamous NSCLC as salvage treatment in Chinese real-world practice. Read More

    Patients' experiences and preferences for opt-in models and health professional involvement in biobanking consent: A cross-sectional survey of Australian cancer outpatients.
    Asia Pac J Clin Oncol 2018 Mar 23. Epub 2018 Mar 23.
    Priority Research Centre for Cancer Research Innovation and Translation, University of Newcastle, Callaghan, NSW, Australia.
    Background: Many biobanks rely upon patients' willingness to donate biospecimens and healthcare professionals to initiate opt-in consent processes. This study explored if: (1) patients accept opt-in or opt-out consent models with varying levels of professional involvement; (2) professionals discuss participation with specific patient groups; and (3) this discussion is associated with patient knowledge of biobanking processes.

    Methods: Outpatients completed surveys at a tertiary cancer center in New South Wales, Australia. Read More

    Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival.
    Asia Pac J Clin Oncol 2018 Mar 23. Epub 2018 Mar 23.
    QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
    Aim: Palliative chemotherapy improves symptom control and prolongs survival in patients with unresectable pancreatic cancer, but there is a paucity of data describing its use and effectiveness in everyday practice. We explored patterns of chemotherapy use in patients with unresected pancreatic cancer in Australia and the impact of use on survival.

    Methods: We reviewed the medical records of residents of New South Wales or Queensland, Australia, diagnosed with unresectable pancreatic adenocarcinoma between July 2009 and June 2011. Read More

    The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage Ⅰ-Ⅲ colorectal cancer.
    Asia Pac J Clin Oncol 2018 Mar 12. Epub 2018 Mar 12.
    Department of Gastrointestinal Surgery, Lab of Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
    Aim: The effects of circulating eosinophils and basophils on cancer survival are unclear. Here, we aimed to explore the impacts of eosinophils and basophils on prognosis of stage I-III colorectal cancer (CRC) patients.

    Methods: From February 2003 to March 2013, 569 stage I-III CRC patients were enrolled in this retrospective study. Read More

    Do FHIT gene alterations play a role in human solid tumors?
    Asia Pac J Clin Oncol 2018 Mar 8. Epub 2018 Mar 8.
    Research Laboratory in Pathology, Graduate Program in Pathology of the Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil.
    The fragile histidine triad (FHIT) gene encloses an active common chromosomal fragile site, FRA3B. This gene is known to be associated with genomic instability, apoptosis and DNA damage. FHIT disturbances have been related to carcinogenesis in different types of human tumor. Read More

    Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
    Asia Pac J Clin Oncol 2018 Mar;14 Suppl 1:7-9
    Hong Kong Pacific Centre, Tsim Sha Tsui, Kowloon, Hong Kong.
    Non-small cell lung cancers (NSCLC) harboring the uncommon epidermal growth factor receptor (EGFR) exon 20 insertion mutations are generally thought to be unresponsive to EGFR-tyrosine kinase inhibitor (TKI) therapy. Presented here is a case of stage IV NSCLC harboring an uncommon EGFR exon 20 insertion mutation that was maintained at minimal progressive disease for 54 months, with 36 months on the second-generation TKI afatinib. Contrary to the existing literature, the patient in this case demonstrated a long, durable response to the EGFR-TKI, which was exhibited by a long survival endpoint. Read More

    Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.
    Asia Pac J Clin Oncol 2018 Mar;14 Suppl 1:4-6
    Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
    A 65-year-old female with diabetes mellitus but otherwise good health in the past suffered from cough with occasional blood-stained sputum during initial presentation. The patient was diagnosed with pulmonary poorly differentiated adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 19 deletion and hence received afatinib therapy for 25 months without obvious adverse events except for a grade 1-2 acneiform rash. The disease was stabilized after subsequent cycles of chemotherapy with pemetrexed and carboplatin followed by maintenance pemetrexed. Read More

    Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite.
    Asia Pac J Clin Oncol 2018 Mar;14 Suppl 1:10-15
    Department of Radiation Oncology, Fraser Valley Cancer Centre, British Columbia Cancer Agency, Canada.
    Aim: The expanded prostate cancer index composite (EPIC) is a widely adopted instrument for the quality of life of patients with prostate cancer. We aimed to create a Chinese version of EPIC to further research in the Chinese-speaking population.

    Methods: A prototype was created by forward-backward translations and revisions. Read More

    A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
    Asia Pac J Clin Oncol 2018 Mar 1. Epub 2018 Mar 1.
    Breast Center, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
    Aim: This multicenter, observational study aimed to investigate the survival benefit of eribulin as well as that of taxane-based regimens in Japanese patients with metastatic breast cancer (MBC) in a real-world setting.

    Methods: This study enrolled women with MBC who received eribulin or taxane-based regimens with or without bevacizumab in routine clinical practice from July 2011 to March 2014. Patients were followed until September 2015. Read More

    Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
    Asia Pac J Clin Oncol 2018 Mar 1. Epub 2018 Mar 1.
    Peter MacCallum Cancer Centre, Victoria, Australia.
    Aim: To characterize the outcomes of patients with nonmelanoma solid tumors receiving anti-PD-1 immunotherapy not funded by the Australian Pharmaceutical Benefits Scheme.

    Methods: Medical records of patients with metastatic nonmelanoma tumor diagnoses treated with anti-PD-1 (self-funded pembrolizumab or nivolumab through an access program) from January 1, 2014, to December 31, 2016, at Peter MacCallum Cancer Centre, were retrospectively reviewed. Events after December 31, 2016, were censored. Read More

    Strong opioid prescription in cancer patients in their final year of life: A population-based analysis using a Taiwanese health insurance database.
    Asia Pac J Clin Oncol 2018 Mar 2. Epub 2018 Mar 2.
    School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan.
    Aim: Pain assessment and management have been important criteria in hospital accreditation in Taiwan since 2007. We used a Taiwanese health insurance database to determine factors influencing patterns of strong opioid use in cancer patients in their final 12 months of life.

    Methods: Data from patients with cancer in Taiwan outpatient clinics with cancer-related deaths between 2008 and 2011 were included in the analysis. Read More

    Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials.
    Asia Pac J Clin Oncol 2018 Jun 2;14(3):125-133. Epub 2018 Mar 2.
    Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
    Toxicities of systemic cancer therapies are often less frequently observed in clinical trials than in clinical practice, due to the careful selection of patients with fewer comorbidities. Although guidelines exist for the estimation of chemotherapy dose, clinical factors like age, comorbid illness and extremes of body habitus are not considered in the method of dose calculation, which can result in significant toxicity. We reviewed the referenced clinical trials from which the evidence-based curative-intent cancer treatment protocols were developed for EVIQ, which is an Australian government, online resource. Read More

    Examining clinicians' perceptions of head and neck cancer (HNC) information.
    Asia Pac J Clin Oncol 2018 Mar 2. Epub 2018 Mar 2.
    Sydney Medical School, University of Sydney, NSW, Australia.
    Background: Providing appropriate educational resources to patients with head and neck cancer (HNC) is important but challenging. The aim of this study was to determine Australian clinicians' perceptions of currently used HNC information resources.

    Methods: A purpose-designed questionnaire was disseminated electronically to clinician members of the Australian and New Zealand Head and Neck Cancer Society (ANZHNCS) and The Australian Society of Otolaryngology Head and Neck Surgery (ASOHNS). Read More

    Leptomeningeal enhancement on preoperative brain MRI in patients with glioblastoma and its clinical impact.
    Asia Pac J Clin Oncol 2018 Feb 23. Epub 2018 Feb 23.
    Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
    Aim: Leptomeningeal enhancement (LME) on preoperative brain magnetic resonance imaging (MRI) does not always indicate leptomeningeal seeding (LMS). With Stupp's regimen, authors have treated glioblastoma patients with LME on preoperative brain MRI but here we tried to find the clinical impact of LME.

    Methods: From 2005 to 2015, 290 patients with glioblastoma have been treated with Stupp's regimen at Samsung Medical Center. Read More

    Uterine adenosarcoma in Japan: Clinicopathologic features, diagnosis and management.
    Asia Pac J Clin Oncol 2018 Feb 14. Epub 2018 Feb 14.
    Department of Gynecology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
    Aim: Uterine adenosarcoma is a rare malignancy with limited cohort data in Asian countries. This study evaluated the clinicopathologic features of Japanese patients with uterine adenosarcoma and their potential treatment challenges.

    Methods: A retrospective chart review was performed at the National Cancer Center Hospital, Japan from 2000 to 2016. Read More

    Investigation of estimated glomerular filtration rate and its perioperative change in patients with upper urinary tract urothelial carcinoma: A multi-institutional retrospective study.
    Asia Pac J Clin Oncol 2018 Feb 12. Epub 2018 Feb 12.
    Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan.
    Aim: To investigate the association of perioperative estimated glomerular filtration rate (eGFR) with prognosis in patients with upper urinary tract urothoelial caicinoma (UTUC).

    Methods: A total of 433 patients underwent radical nephroureterectomy with excision of the bladder cuff (RNU) at six hospitals affiliated with Kitasato University in Japan. Patients were divided into three groups each in terms of preoperative eGFR: normal eGFR (>60 mL/min/1. Read More

    Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.
    Asia Pac J Clin Oncol 2018 Jun 31;14(3):153-158. Epub 2018 Jan 31.
    Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
    Aim: Sunitinib is a standard agent for metastatic renal cell carcinoma (mRCC). The standard schedule, 4 weeks-on followed by 2 weeks-off (4/2 schedule), often does not maintain an adequate dosage because of the severe adverse events (AEs). We compared the efficacy and safety of an alternative every other day (q. Read More

    FLT3-ITD positive acute myeloid leukemia: A retrospective analysis of the role of allogeneic transplant and allelic ratio in patient management.
    Asia Pac J Clin Oncol 2018 Jan 31. Epub 2018 Jan 31.
    Cancer Care Services, Royal Brisbane and women's Hospital, Brisbane, Australia.
    Aim: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) positive AML is associated with increased relapse risk and reduced overall survival (OS) compared to non-FLT3-mutated AML. The aim of this study was to evaluate the impact of allelic ratio and allogeneic transplant on outcomes in FLT3-ITD+ AML.

    Methods: A retrospective study across five centers in Queensland, Australia, was conducted to examine survival outcomes and impact of FLT3-ITD allelic ratio and allograft. Read More

    Patterns of care of superficial soft tissue sarcomas: it is not always just a lump.
    Asia Pac J Clin Oncol 2018 Jan 31. Epub 2018 Jan 31.
    Prince of Wales Hospital Clinical School, Faculty of Medicine, University of New South Wales, Australia.
    Aim: Superficial soft tissue sarcomas (S-STS) are generally considered low-risk tumors and have an excellent prognosis when treated with appropriate surgery and adjuvant therapy. However, they are often misdiagnosed then mistreated, leading to significant morbidity. This study aims to examine the patterns of care and outcomes of patients with S-STS, comparing those initially managed through sarcoma units versus elsewhere. Read More

    Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAseq datasets.
    Asia Pac J Clin Oncol 2018 Jan 30. Epub 2018 Jan 30.
    University School of Biotechnology, Guru Gobind Singh Indraprastha University, Dwarka, New Delhi, India.
    Aim: To evaluate the diagnostic potential of a six microRNAs (miRNAs) panel consisting of miR-21, miR-144, miR-107, miR-342, miR-93 and miR-152 for esophageal cancer (EC) detection.

    Methods: The expression of miRNAs was analyzed in EC sera samples using quantitative real-time PCR. Risk score analysis was performed and linear regression models were then fitted to generate the six-miRNA panel. Read More

    Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
    Asia Pac J Clin Oncol 2018 Jan 30. Epub 2018 Jan 30.
    University of Sydney, Sydney Adventist Hospital, SAN Integrated Cancer Centre, Wahroonga, New South Wales, Australia.
    Aromatase inhibitors are the gold standard in the treatment of hormone receptor-positive breast cancer, but lead to an arthralgia syndrome which is implicated in 13-22% of noncompliance. This is the first systematic review of the efficacy of existing management strategies for this side effect. Eligible studies were retrieved from computer searches of Medline, Cochrane and Embase and the significant intervention groups were identified. Read More

    A mixed methods analysis of experiences and expectations among early-career medical oncologists in Australia.
    Asia Pac J Clin Oncol 2018 Jan 26. Epub 2018 Jan 26.
    Department of Medical Oncology, Royal Brisbane and Women's Hospital, Queensland, Australia.
    Aim: A viable and sustainable medical oncology profession is integral for meeting the increasing demand for quality cancer care. The aim of this study was to explore the workforce-related experiences, perceptions and career expectations of early-career medical oncologists in Australia.

    Methods: A mixed-methods design, including a survey (n  =  170) and nested qualitative semistructured interviews (n  =  14) with early-career medical oncologists. Read More

    Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and safety data from the ML17032 phase III clinical trial.
    Asia Pac J Clin Oncol 2018 Jan 26. Epub 2018 Jan 26.
    Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangdong, China.
    Aim: To confirm non-inferiority and test potential superiority of capecitabine/cisplatin (XP) over 5-fluorouracil (5-FU)/cisplatin (FP) as first-line treatment for advanced gastric cancer (AGC) in Chinese patients.

    Methods: In open-label phase III ML17032 trial, AGC (stage IIIA-IV) patients with or without metastases were randomized 1:1 to receive cisplatin (80 mg/m /day intravenous [IV] day 1) with either capecitabine (1000 mg/m /day oral [PO] twice daily [BID], days 1-14; XP) or 5-FU (800 mg/m /day continuous IV days 1-5; FP) every 3 weeks. The primary objective was to confirm the non-inferiority of XP over FP for progression-free survival (PFS). Read More

    Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
    Asia Pac J Clin Oncol 2018 Jan 25. Epub 2018 Jan 25.
    Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
    Aim: To better understand the T-cell immunodeficiency status in patients with peripheral T-cell lymphomas (PTCLs) and NK/T-cell lymphomas (NK/T-CLs), the T-cell inhibitory receptors expression pattern was investigated.

    Methods: The expression levels of programmed death 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), B/T lymphocyte attenuator (BTLA), lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin-3 (TIM-3), T-cell immunoglobulin and ITIM domain (TIGIT) genes were detected in peripheral blood mononuclear cells (PBMCs) from patients and healthy volunteers by quantitative real-time-PCR, the correlation between different gene expression levels was analyzed.

    Results: Significantly higher expression of PD-1, CTLA-4, BTLA, LAG-3, TIM-3 and TIGIT can be observed as a common characteristic in patients with PTCL or NK/T-CL. Read More

    Impact of body mass index on the oncological outcomes of patients with upper and lower urinary tract cancers treated with radical surgery: A multi-institutional retrospective study.
    Asia Pac J Clin Oncol 2018 Jan 22. Epub 2018 Jan 22.
    Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan.
    Aim: To evaluate the impact of body mass index (BMI) on the oncological outcomes of urothelial carcinoma (UC) patients.

    Patients And Methods: We retrospectively analyzed data from 818 patients with upper tract urothelial cancer (UTUC) and bladder cancer (BC) who were treated with radical nephroureterectomy (RNU) or radical cystectomy (RC) between 1990 and 2015 at six different institutions in Japan. Patients with distant metastasis at diagnosis and those who received neoadjuvant therapies were excluded, leaving 727 eligible patients (UTUC: n = 441; BC: n = 286). Read More

    Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis.
    Asia Pac J Clin Oncol 2018 Jun 19;14(3):141-152. Epub 2018 Jan 19.
    Cancer Care Centre, St George Hospital, Gray Street, Kogarah, Sydney, NSW, Australia.
    Background: We performed a meta-analysis to quantify toxic death, adverse events (AEs) and treatment discontinuation due to AEs from checkpoint inhibitors (CI).

    Methods: We searched for randomized trials with adequate reporting for toxicity outcomes. Pooled risk ratios were estimated for CI versus chemotherapy or different combinations of these agents. Read More

    High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.
    Asia Pac J Clin Oncol 2018 Jan 17. Epub 2018 Jan 17.
    Department of Medical Oncology, Alfred Health, Melbourne, Australia.
    Aim: To evaluate the role of neutrophil-to-lymphocyte ratio as a prognostic marker in squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.

    Methods: A retrospective chart review was performed on patients presenting to our service between 2001 and 2014. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier estimates. Read More

    Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma.
    Asia Pac J Clin Oncol 2018 Jan 16. Epub 2018 Jan 16.
    Sydney Medical School, University of Sydney, Sydney, Australia.
    Introduction: Ki-67 proliferation index (Ki-67 index) is used to quantify cell proliferation during histopathological assessment of various tumors including glioblastoma (GB).

    Aim: We aimed to assess correlation between Ki-67 index and overall survival in patients with GB and determine a cut-point for Ki-67 index that predicts for poorer survival.

    Method: Records of adult patients diagnosed with GB on histopathological specimens at a tertiary cancer center in Sydney between 1 January 2002 and 30 July 2012 were retrieved. Read More

    Complications of curative radiation treatment for early prostate cancer.
    Asia Pac J Clin Oncol 2018 Jan 16. Epub 2018 Jan 16.
    Canterbury District Health Board, Christchurch Hospital, Christchurch, New Zealand.
    Aim: To report the incidence of urological complications following curative radiation treatment for early prostate cancer, including minimally invasive urological procedures (MUIP), hospital admissions and open surgical procedures. Second malignancies following radiation are also reported and compared with patients undergoing a prostatectomy.

    Methods: Included were patients receiving curative intent external beam radiation treatment for early prostate cancer between January 1, 2002, and December 31, 2009. Read More

    MAML1 and TWIST1 co-overexpression promote invasion of head and neck squamous cell carcinoma.
    Asia Pac J Clin Oncol 2018 Jan 15. Epub 2018 Jan 15.
    Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran.
    Aims: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with considerable morbidity and mortality. Invasion and metastasis of HNSCC is a complex process involving multiple molecules and signaling pathways. Twist Family BHLH Transcription Factor 1 (TWIST1) and Mastermind-like 1 (MAML1) are essential in induction of epithelial-mesenchymal transition through direct regulation of implicated molecules in cellular adhesion, migration and invasion. Read More

    Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer.
    Asia Pac J Clin Oncol 2018 Jun 10;14(3):204-209. Epub 2018 Jan 10.
    Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
    Aim: We describe a subgroup analysis assessing the efficacy and safety of ramucirumab monotherapy in East Asian (EA) patients from the REGARD trial.

    Methods: Patients with advanced gastric or gastroesophageal junction adenocarcinoma with progressive disease were randomized 2:1 to receive ramucirumab (8 mg/kg) plus best supportive care (BSC) or placebo plus BSC every 2 weeks. Post hoc subset analyses were performed on the EA and non-EA intention-to-treat populations. Read More

    1 OF 17